Register
Login:
Share:
Email Facebook Twitter


James Bevan on cybersecurity, banks and the housing market


Summit Ther Share Price (SUMM)



Share Price Information for Summit Ther (SUMM)


Share Price: 177.50Bid: 170.00Ask: 185.00Change: 0.00 (0.00%)No Movement on Summit Ther
Spread: 15.00Spread as %: 8.82%Open: 177.50High: 177.50Low: 177.50Yesterday’s Close: 177.50

Summit Therapeutics Plc Ord 1P

Summit Ther is listed in the FTSE AIM All-Share
Summit Ther is part of the Medicine and Biotech Research sector






Share Price SpacerPrice
177.50

Share Price SpacerBid
170.00

Share Price SpacerAsk
185.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
2,274

Share Price SpacerOpen
177.50

Share Price SpacerHigh
177.50

Share Price SpacerLow
177.50

Share Price SpacerClose
177.50

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 61.91m £109.89m 1,500

52 Week High 260.00 52 Week High Date 4-OCT-2016
52 Week Low 90.00 52 Week Low Date 16-SEP-2016

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
3 2,216 58 -5.071 -35.00 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

23-May-17
16:13:20
175.00
1,716
Sell* 
170.00
185.00
3,003
Trade Type:
Ordinary

23-May-17
15:32:39
175.00
500
Sell* 
170.00
185.00
875.00
Trade Type:
Ordinary

23-May-17
11:15:46
182.00
58
Buy* 
170.00
185.00
105.56
Trade Type:
Ordinary




View more Summit Ther trades >>

Directors Deals for Summit Ther (SUMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
18-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
David Wurzer held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 David Wurzer
2.33USD7,5007500
17-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Valerie Andrews held the position of Non-Executive Director at Summit Therapeutics at the time of this trade.
 Valerie Andrews
2.3USD10,50010500
16-Jun-15Buy
Trade Notifier Information for Summit Therapeutics
Frank Armstrong held the position of Non-Executive Chairman at Summit Therapeutics at the time of this trade.
 Frank Armstrong
2.34USD4,25014442
View more Summit Ther directors dealings >>



Date/TimeAuthorSubjectShare PriceOpinion
Tue 20:06gmccSUMM new stafff177.50No Opinion
Dr Robin taking on more responsibility + two new appointments with some big pharma experience ! Sounds promising presumably liked what the heard about the drugs prospects !!!!!!!!!!!-

Dr David Roblin added, "In the coming 12 months, Summit has the potential to achieve proof of concept with ezutromid in the treatment of DMD and plans to begin Phase 3 trials for ridinilazole in CDI, each step potentially bringing us closer to making a difference for patients and families… Read More
Mon 11:49ChrisatrdgAGM177.50Strong Buy
Hi Free-Money - I am going to AGM this year & went last year so see you there.I am also fully invested & confident although I did some de-risking last October now owning 40k shares (54% up).I started investing in Feb. 2010 & it has had many ups & downs but I now think we are in the final stretch in the next 12 months.I am looking forward to the summer & that C-Diff deal.
Mon 11:09Free-MoneyAGM177.50Strong Buy
As I'm still fully invested and confident in Summit delivering to plan now I'll be going to the AGM on the 18th July.
Anyone else going?
It would be great to meet up.
"The Annual General Meeting will be held at 11:00am BST on Tuesday, 18 July 2017 at the Milton Park Innovation Centre, 99 Park Drive, Abingdon, Oxfordshire, OX14 4RY, UK"
Mon 10:52pomanderRE: Conferences sch updated177.50No Opinion
I don't believe the Sarepta deal has directly solved any problems for funding C-Diff's progression. I find it inconceivable that Sarepta would pay over $22m and allow it to be expended on furthering the C-Diff program.

The value of the Sarepta deal is that Summ no longer has to raise funds, from whatever source, to fund two programs, so if it is able to raise money from whatever source in the Summer, it can be allocated entirely to C-Diff should management decide to do so.

I remain… Read More
Mon 10:26gmccRE: Conferences sch updated177.50No Opinion
Sorry Touch of Déjà vu about this thread !

Expectation previously was a partner required ASAP for a c-diff deal necessary to help fund the DMD programme.

Sarepta deal has solved that problem , so no immediate urgency to complete c-diff deal although will admit bit disappointed that P3 c-diff trial will not start before 1H 2018

As stated Summit management looking at a few funding options and decision will be announced in the Summer .

Be it… Read More
Sun 22:27pomanderRE: Conferences sch updated177.50No Opinion
Don't follow your logic - we were discussing C-Diff and then you throw in DMD.

You are missing the point , Big-pharma are not concerned about cost of completing P3 trials - it is the return from a C-Diff drug/new antibiotic that is the concern & factors such as government intervention.

If the cost are so negligible and the commercial prospects so huge why no no deal? You seem to be arguing against yourself.

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Summit Ther (SUMM) >>

Please login or register to post a message on Share Chat.








Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk








Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.